The Predictive Value of HER2 in Breast Cancer

@article{Piccart2001ThePV,
  title={The Predictive Value of HER2 in Breast Cancer},
  author={Martine J Piccart and Caroline A. Lohrisch and Angelo Di Leo and Denis Larsimont},
  journal={Oncology},
  year={2001},
  volume={61},
  pages={73 - 82}
}
Measurement of molecular markers predictive of response to therapy should enable more selective and effective utilization of anticancer agents. The predictive value of HER2 remains a complex and inconclusive subject. In metastatic breast cancer, HER2-positive, ER-positive patients can show responses to endocrine treatment, but experience shorter time to progression and survival than HER2-negative patients. In the adjuvant setting, weak, retrospective evidence suggests that tamoxifen is… 

Figures and Tables from this paper

HER2 Testing in Breast Cancer: Opportunities and Challenges
TLDR
The molecular background of HER2 function, activation and inhibition as well as current opinions concerning its role in chemosensitivity and interaction with estrogen receptor biology are reviewed.
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
TLDR
High levels of HER2 are associated with achievement of a pathCR in the preoperative setting, while levels of Phospho-HER2 were not predictive of response, which suggests that accurate measurement of Her2 may help determine the likelihood of response in thePreoperative setting.
Role of Herceptin® in Primary Breast Cancer: Views from North America and Europe
TLDR
A number of trials are described that aim to provide conclusive evidence as rapidly as possible that Herceptin is well tolerated and effective in the adjuvant setting while also addressing the question of which regimen provides greatest benefit.
Testing for HER2 Status
TLDR
A Canadian Her2 testing algorithm designed to increase the validity and reproducibility of HER2 testing has been compiled and shows a high level of concordance.
The role of platinum-based therapy for HER-2-positive breast cancer
TLDR
The pre-clinical and rapidly evolving clinical evidence supporting platinum and trastuzumab combinations for HER-2-positive breast cancer is reviewed.
Breast cancer—the role of the pathologist and targeted therapies/optimal pathology reporting
TLDR
The data on the prognostic and predictive utility of HER2 status in the adjuvant and metastatic settings are reviewed and the advantages and disadvantages of the two most common methodologies are elucidated.
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
TLDR
The review concludes with a consideration of HER-2 status in the prediction of response to non-HER-2 targeted treatments including hormonal therapy, anthracyclines, and taxanes.
HER2 as a Predictive Factor for Successful Neoadjuvant Anthracycline Chemotherapy of Locally Advanced and Early Breast Cancer
TLDR
Her2 overexpression in primary tumors might be a predictive marker for good efficacy of anthracycline-based neoadjuvant chemotherapy, and the pCR is a suitable prognostic factor, even for patients with HER2 overeexpression.
Targeted therapy of breast cancer.
TLDR
Tastuzumab, a humanized monoclonal antibody to HER-2, is the first molecular targeting agent approved for therapy of metastatic breast cancer, capable to significantly improve clinical outcome in combination with cytotoxic therapy.
Endocrine resistance in breast cancer – An overview and update
...
...

References

SHOWING 1-10 OF 69 REFERENCES
Assessment of HER2 status in breast cancer: why, when and how?
Role of Herceptin® in Primary Breast Cancer: Views from North America and Europe
TLDR
A number of trials are described that aim to provide conclusive evidence as rapidly as possible that Herceptin is well tolerated and effective in the adjuvant setting while also addressing the question of which regimen provides greatest benefit.
Testing for HER2 Status
TLDR
A Canadian Her2 testing algorithm designed to increase the validity and reproducibility of HER2 testing has been compiled and shows a high level of concordance.
The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2.
  • A. HamiltonM. Piccart
  • Medicine, Psychology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2000
TLDR
There is inadequate evidence to support the use of HER-2, p53 or BCL-2 to guide the selection of hormonal therapy, chemotherapy or radiotherapy for breast cancer.
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
  • R. ElledgeS. Green C. Osborne
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1998
TLDR
HER-2/neu expression in ER-positive metastatic breast cancer is not significantly associated with a poorer response to tamoxifen or a more aggressive clinical course, and earlier suggestions to the contrary may have been due to failure to rigorously exclude ER-negative tumors.
p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
PURPOSE Thirty percent of women with node-negative breast cancer will have a recurrence within 10 years after diagnosis. Molecular markers may identify those patients and predict whether they benefit
Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.
  • H. YamauchiA. O'neill D. Hayes
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
TLDR
Pretreatment circulating NRP levels predict a low likelihood of benefit from HT, specifically DRO, in patients with estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive or receptor-unknown metastatic breast cancer, even when adjusted for other known predictive factors.
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
  • M. CobleighC. Vogel D. Slamon
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
TLDR
Recombinant humanized anti-HER2 monoclonal antibody, administered as a single agent, produces durable objective responses and is well tolerated by women with HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
TLDR
The hypothesis that patients whose breast tumors exhibit high erbB-2 expression benefit from dose-intensive CAF should be further validated before clinical implementation.
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
TLDR
In patients with ER-positive primary tumours, the overexpression of c-erbB2 defines a subgroup less likely to respond to endocrine Therapy, an independent marker of relative resistance to first-line endocrine therapy in patients with advanced breast cancer.
...
...